148 related articles for article (PubMed ID: 14617798)
41. Computational design and experimental discovery of an antiestrogenic peptide derived from alpha-fetoprotein.
Kirschner KN; Lexa KW; Salisburg AM; Alser KA; Joseph L; Andersen TT; Bennett JA; Jacobson HI; Shields GC
J Am Chem Soc; 2007 May; 129(19):6263-8. PubMed ID: 17441722
[TBL] [Abstract][Full Text] [Related]
42. The recombinant third domain of human alpha-fetoprotein retains the antiestrotrophic activity found in the full-length molecule.
Festin SM; Bennett JA; Fletcher PW; Jacobson HI; Shaye DD; Andersen TT
Biochim Biophys Acta; 1999 Apr; 1427(2):307-14. PubMed ID: 10216247
[TBL] [Abstract][Full Text] [Related]
43. Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted C(α) amino acids.
Hicks RP
Bioorg Med Chem; 2016 Sep; 24(18):4056-4065. PubMed ID: 27387357
[TBL] [Abstract][Full Text] [Related]
44. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.
Tada N; Horibe T; Haramoto M; Ohara K; Kohno M; Kawakami K
Biochem Biophys Res Commun; 2011 Apr; 407(2):383-8. PubMed ID: 21396910
[TBL] [Abstract][Full Text] [Related]
45. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
46. Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro.
Muraoka A; Tokiwa T; Sato J
Br J Cancer; 1989 Apr; 59(4):569-72. PubMed ID: 2469455
[TBL] [Abstract][Full Text] [Related]
47. A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture.
Sierralta WD; Epuñan MJ; Reyes JM; Valladares LE; Andersen TT; Bennett JA; Jacobson HI; Pino AM
Oncol Rep; 2008 Jan; 19(1):229-35. PubMed ID: 18097600
[TBL] [Abstract][Full Text] [Related]
48. Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation.
Ortuso F; Paduano F; Carotenuto A; Gomez-Monterrey I; Bilotta A; Gaudio E; Sala M; Artese A; Vernieri E; Dattilo V; Iuliano R; Brancaccio D; Bertamino A; Musella S; Alcaro S; Grieco P; Perrotti N; Croce CM; Novellino E; Fusco A; Campiglia P; Trapasso F
ACS Chem Biol; 2013 Jul; 8(7):1497-506. PubMed ID: 23627474
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxic action of conjugates of alpha-fetoprotein and epidermal growth factor with photoheme, chlorines, and phthalocyanines.
Savitsky AA; Gukasova NV; Gumanov SG; Feldman NB; Luk'yanets EA; Mironov AF; Yakubovskaya RI; Lutsenko SV; Severin SE
Biochemistry (Mosc); 2000 Jun; 65(6):732-6. PubMed ID: 10887296
[TBL] [Abstract][Full Text] [Related]
50. Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro.
Severin SE; Moskaleva EYu ; Shmyrev II; Posypanova GA; Belousova YuV ; Sologub VK; Luzhkov YuM ; Nakachian R; Andreani J; Severin ES
Biochem Mol Biol Int; 1995 Oct; 37(2):385-92. PubMed ID: 8673023
[TBL] [Abstract][Full Text] [Related]
51. Cephalostatin analogues--synthesis and biological activity.
Flessner T; Jautelat R; Scholz U; Winterfeldt E
Fortschr Chem Org Naturst; 2004; 87():1-80. PubMed ID: 15079895
[TBL] [Abstract][Full Text] [Related]
52. Structure-based design for binding peptides in anti-cancer therapy.
Wang SH; Yu J
Biomaterials; 2018 Feb; 156():1-15. PubMed ID: 29182932
[TBL] [Abstract][Full Text] [Related]
53. [Epitopic multiple antigen peptide from α-fetoprotein elicit antitumor immune response in vitro and ex vivo].
Fan ZJ; Zhang SR
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1138-42. PubMed ID: 22781777
[TBL] [Abstract][Full Text] [Related]
54. Recent Progress of Marine Polypeptides as Anticancer Agents.
Zheng L; Xu Y; Lin X; Yuan Z; Liu M; Cao S; Zhang F; Linhardt RJ
Recent Pat Anticancer Drug Discov; 2018; 13(4):445-454. PubMed ID: 29708076
[TBL] [Abstract][Full Text] [Related]
55. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy.
Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K
Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640
[TBL] [Abstract][Full Text] [Related]
56. Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.
Venneti KC; Malthouse JP; O'Harte FP; Hewage CM
Biochim Biophys Acta; 2011 Jul; 1814(7):882-8. PubMed ID: 21539943
[TBL] [Abstract][Full Text] [Related]
57. In vitro bioassays for anticancer drug screening: effects of cell concentration and other assay parameters on growth inhibitory activity.
Lieberman MM; Patterson GM; Moore RE
Cancer Lett; 2001 Nov; 173(1):21-9. PubMed ID: 11578805
[TBL] [Abstract][Full Text] [Related]
58. Substance P analogs containing alpha,alpha-dialkylated amino acids with potent anticancer activity.
Prasad S; Mathur A; Jaggi M; Singh AT; Mukherjee R
J Pept Sci; 2007 Aug; 13(8):544-8. PubMed ID: 17617800
[TBL] [Abstract][Full Text] [Related]
59. Design, Synthesis, and Biological Evaluation of New Peptide Analogues as Selective COX-2 Inhibitors.
Ahmaditaba MA; Shahosseini S; Daraei B; Zarghi A; Houshdar Tehrani MH
Arch Pharm (Weinheim); 2017 Oct; 350(10):. PubMed ID: 28872704
[TBL] [Abstract][Full Text] [Related]
60. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
